Incyte and Genesis Partner on AI-driven Small Molecule Drug Discovery
American multinational pharma company Incyte and AI-focused biotech Genesis Therapeutics have announced a strategic collaboration to leverage artificial intelligence for the discovery and development of novel small-molecule therapeutics. The partnership will focus on Incyte-selected targets, with Genesis utilising its proprietary AI platform, GEMS (Genesis Exploration of Molecular Space), to identify and optimise potential drug candidates. Incyte will hold exclusive rights to develop and commercialize any resulting products.
AI-Powered Innovation in Drug Discovery
Genesis Therapeutics is a pioneer in applying generative and predictive AI technologies to drug discovery. Its GEMS platform integrates advanced AI methods, including language models, diffusion models, and physical simulations, to tackle complex therapeutic targets. This collaboration aims to accelerate the discovery of breakthrough treatments for patients with severe diseases.
Pablo J. Cagnoni, M.D., President and Head of Research and Development at Incyte, stated:
“As a leader in pharmaceutical innovation, Incyte is continually seeking new technologies that can transform how new medicines are discovered and developed. Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the discovery of breakthrough small molecules for high-impact targets in our pipeline.”
Evan Feinberg, Ph.D., Founder and Chief Executive Officer of Genesis, added:
“AI has the potential to redefine how we discover small molecule medicines, and our team is at the forefront of this revolution. We are pleased to establish this world-class partnership to combine our GEMS AI platform with Incyte’s deep expertise and track record in drug discovery and development, with the shared goal of advancing critical treatments for patients with severe diseases.”
Financial Terms and Milestones
Under the agreement, Genesis will receive an upfront payment of $30 million. The collaboration will initially focus on two targets selected by Incyte, with the option for Incyte to nominate an additional target for a predetermined fee. If all development, regulatory, and commercial milestones are achieved, Genesis could receive up to $295 million per target. Genesis is also eligible for tiered royalties on sales of any approved collaboration products.
About Genesis Therapeutics
Genesis Therapeutics, Inc. is an AI-focused biotechnology company leveraging its GEMS platform for small molecule drug discovery. The company has raised over $300 million from leading life science, tech, and AI-focused investors and is building a pipeline of therapeutics for high-impact diseases. Headquartered in Burlingame, California, Genesis operates a fully integrated laboratory in San Diego. For more information, visit www.genesistherapeutics.ai.
About Incyte
Incyte is a global biopharmaceutical company dedicated to addressing unmet medical needs through innovative science. With a focus on Oncology and Inflammation & Autoimmunity, Incyte has developed a portfolio of first-in-class medicines and maintains a strong pipeline of potential therapies. Headquartered in Wilmington, Delaware, Incyte operates across North America, Europe, and Asia. For more information, visit www.incyte.com.
This partnership highlights the growing role of AI in transforming drug discovery, with the potential to deliver life-changing treatments for patients worldwide.
Original Source: WILMINGTON, Del. & BURLINGAME, Calif.–(BUSINESS WIRE)–Incyte (Nasdaq:INCY) and Genesis Therapeutics, Inc., February 20, 2025: Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
Recommended Companies
Ad
More Headlines
